Cachexia is a complex multifactorial syndrome, characterized by loss of skeletal muscle and
fat mass, which affects the majority of advanced cancer patients and is associated with poor …

Duchenne muscular dystrophy is a highly progressive muscle wasting disorder due to
primary abnormalities in one of the largest genes in the human genome, the DMD gene …

Muscular Dystrophy, convened a Working Group meeting on July 2014, in Bethesda, MD, to
explore clinical and research questions related to cardiac disease in patients with DMD. As …

It is expected that serum protein biomarkers in Duchenne muscular dystrophy (DMD) will
reflect disease pathogenesis, progression and aid future therapy developments. Here, we …

Numerous biomarkers have been unveiled in the rapidly evolving biomarker discovery field,
with an aim to improve the clinical management of disorders. In rare diseases, such as …

Assessments of disease progression and response to therapies in Duchenne muscular
dystrophy (DMD) patients remain challenging. Current DMD patient assessments include …

Background Identifying translatable, non-invasive biomarkers of muscular dystrophy that
better reflect the disease pathology than those currently available would aid the …

Idiopathic steroid sensitive nephrotic syndrome (INS), the most frequent childhood
nephropathy, is thought to be mediated by a circulating soluble factor that reversibly affects …

The contractile function of striated muscle cells is altered by oxidative/nitrosative stress,
which can be observed under physiological conditions but also in diseases like heart failure …

Duchenne muscular dystrophy (DMD) is caused by genetic deficiency of dystrophin and
characterized by massive structural and functional changes of skeletal muscle tissue …